India Maintains Firm Stance Against Patent Evergreening in Global Trade Negotiations
核心洞察
India's Commerce and Industry Minister Piyush Goyal reaffirmed the nation's commitment to preventing patent evergreening despite pressure from multinational pharmaceutical companies.
Sections 3(d) and 3(b) of the Indian Patents Act, 1970, continue to restrict patents on known drugs unless they demonstrate significant efficacy improvements over existing products.
India has successfully maintained robust intellectual property rights chapters in trade agreements with the UK and EFTA (搜索) while preserving anti-evergreening protections.
India's Commerce and Industry Minister Piyush Goyal has reinforced the nation's unwavering position against patent evergreening, maintaining critical protections for public health despite mounting pressure from multinational pharmaceutical companies. The minister's statements come amid ongoing trade negotiations with developed nations, where India has successfully preserved its anti-evergreening stance while securing robust intellectual property rights chapters.
Legislative Framework Remains Intact
India's patent protection framework continues to center on Sections 3(d) and 3(b) of the Indian Patents Act, 1970, which serve as crucial barriers against unwarranted patent extensions. Section 3(d) specifically restricts patents for already-known drugs unless new claims demonstrate superior efficacy, while Section 3(b) bars patents for products that contradict public interest and fail to show enhanced efficacy over existing treatments.
These provisions have faced significant opposition from certain multinational firms seeking amendments to the legislation. However, Indian authorities have strongly resisted such calls, viewing these protections as integral to preventing pharmaceutical companies from extending monopolies through minor modifications to existing drugs.
Patent Evergreening Strategy Explained
Patent evergreening represents a strategy allegedly employed by innovator companies to renew patent rights by introducing minor changes such as new mixtures or formulations when their original patents near expiration. This practice effectively extends monopoly periods, as patents on new forms would grant innovator companies an additional 20-year exclusive market position.
Pharmaceutical firms from countries including Switzerland and the UK have been particularly vocal in demanding evergreening provisions, highlighting the international pressure India faces in maintaining its current legislative stance.
Trade Agreement Success
Despite these challenges, Minister Goyal emphasized India's success in negotiating robust intellectual property rights chapters in free trade agreements with both the UK and the four-nation EFTA (搜索) bloc. "We will not allow any ever greening," Goyal stated, adding that "we still have a robust IPR chapter with two of the toughest countries of the world in IPR - Switzerland and the UK."
The minister characterized these achievements as "a big signal that India is emerging out of the shadows and sitting on a high table with developed countries," indicating the nation's growing influence in international IPR negotiations.
Strategic Implications
India's firm stance reflects broader concerns about maintaining affordable access to essential medications while balancing international trade relationships. The country's approach demonstrates how developing nations can preserve public health protections while engaging constructively in global trade frameworks.
The successful negotiation of these agreements while maintaining anti-evergreening protections suggests that India's position has gained international recognition and acceptance, even among traditionally stringent IPR enforcement advocates.